66th ASH Annual Meeting: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II

Symposia: Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution Oral and Poster Abstracts
Poster

Research, Antibody Therapy, Sickle Cell Disease, Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, Combination therapy, AML, MDS, Fundamental Science, Clinical trials, Adult, Clinical Practice (Health Services and Quality), Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Lymphomas, MPN, Translational Research, Epidemiology, Autoimmune hemolytic anemia, Aplastic Anemia, Thalassemia, B Cell lymphoma, CML, Clinical Research, Health outcomes research, Hemoglobinopathies, GVHD, T Cell lymphoma, Chronic Myeloid Malignancies, CMML, Pediatric, Education, Supportive Care, Diseases, Immune Disorders, Immunodeficiency, SARS-CoV-2/COVID-19, Treatment Considerations, Infectious Diseases, Biological therapies, Immunology, Real-world evidence, Adverse Events, Lymphoid Malignancies, Computational biology, Registries, Young adult , Biological Processes, Myeloid Malignancies, Survivorship, Technology and Procedures, Study Population, Human, Transplantation (Allogeneic and Autologous)

Halls G-H (San Diego Convention Center)

3515

Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects

Yuhua Ru¹^*, Jinjin Zhu²^*, Huanle Gong, PhD³^*, Mimi Xu, MD¹^*, Ying Wang⁴^*, Miao Miao, MD⁵^*, Suning Chen, MD, PhD⁶^*, Xiang Zhang⁷^*, Yi Fan⁸^*, Yang Xu³^*, Jia Chen⁵^* and Depei Wu, MD, PhD⁹

¹The First Affiliated Hospital of Soochow University, Suzhou, CHN
²The first affiliated hospital of Soochow University, Suzhou, China
³The First Affiliated Hospital Of Soochow University, Suzhou, China
⁴The First Affiliated Hospital of Soochow University, Suzhou, China
⁵National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
⁶The first Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
⁷Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁸The First Affilliated Hospital of Soochow University, Suzhou, CHN
⁹Department of Hematology, the First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China

3516

Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)

Lev Gorfinkel, MD^1,2,3, Muna Qayed, MD⁴, Brandi Bratrude⁵^*, Kayla Betz, BS⁶^*, Kyle Hebert, MS⁷^*, Sung W. Choi, MD, MS⁸, Jeffrey Davis⁹^*, Christine Duncan^10,11,12, Roger H. Giller, MD¹³^*, Michael S. Grimley, MD¹⁴, Andrew Harris, MD¹⁵^*, David A Jacobsohn, MD¹⁶, Nahal Lalefar, MD¹⁷^*, Nosha Farhadfar, MD¹⁸^*, Michael A. Pulsipher, MD¹⁹, Shalini Shenoy, MD²⁰, Aleksandra Petrovic, MD²¹^*, Kirk R. Schultz, MD²², Gregory Yanik, MD²³^*, Bruce R Blazar, MD²⁴, John T. Horan, MD²⁵, Amelia Langston, MD²⁶, Leslie Kean, MD²⁷ and Benjamin Watkins, MD²⁸

¹Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA
²Harvard Medical School, Boston, MA
³Dana-Farber Cancer Institute, Boston, MA
⁴Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
⁵Boston Children's Hospital, Boston
⁶Boston Children's Hospital, boston, MA
⁷Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁸Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI
⁹BC Children's Hospital, Oak Harbor, WA
¹⁰Division of Pediatric Hematology/Oncology, Boston Children’s Hospital, Boston, MA
¹¹Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
¹²Department of Pediatrics, Harvard Medical School, Boston, MA
¹³University of Colorado SOM / Childrens Hospital Colorado, Denver, CO
¹⁴Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
¹⁵Pediatric Stem Cell Transplantation and Cellular Therapies Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁶Children's National Medical Center, Washington, DC
¹⁷UCSF Benioff Children's Hospital Oakland, Oakland, CA
¹⁸University of Florida, Gainesville, FL
¹⁹Huntsman Cancer Institute, Salt Lake City, UT
²⁰Department of Pediatrics, Division of Hematology / Oncology, Washington University Medical Center, Saint Louis, MO
²¹Fred Hutchinson Cancer Center, Seattle, WA
²²B.C. Children's Hospital, Vancouver, BC, Canada
²³Rogel Cancer Center, University of Michigan, Ann Arbor, MI
²⁴Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN
²⁵University of Rochester Medical Center, Rochestser
²⁶Emory University, Winship Cancer Institute, Atlanta, GA
²⁷Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA
²⁸Tulane University, New Orleans

3517

Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Muhammad Umair Mushtaq^1,2,3, Amir Kasaeian^2,3^*, Muhammad Kashif Amin, MD^1,2,3^*, Hediyeh Alemi^2,3^*, Naghmeh Khavandgar^2,3^*, Aqeeb Ur Rehman, MD^2,3^*, Sibgha Gull Chaudhary, MD^2,3^*, Matthew McGuirk^2,3^*, Al-Ola Abdallah, MD^1,2, Anurag K. Singh, MD^1,2,3, Sunil Abhyankar, MD^1,2,3, Mehdi Hamadani, MD^3,4, Joseph P. McGuirk, DO^1,2,3 and Moazzam Shahzad, MD^2,3,5

¹US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
²Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
³Mikael Rayaan Foundation Global Health Consortium, Kansas City, KS
⁴Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
⁵Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL

3518

Abatacept Abrogates the Risk of Acute GvHD in Both Matched and Mismatched Transplantation for Haemoglobinopathies and Bone Marrow Failure

Daniel Dexter, MBBS¹^*, Farah O'Boyle²^*, Kirstin Lund, MRCP, BSc³^*, Toni Petterson⁴^*, Adam Gassas, MD⁵^*, Leena Karnik, FRCPath, MRCP⁶^*, Josu de la Fuente, PhD FRCP^7,8,9, Sandrine Bremathas, RN¹⁰^* and Kelly Hennessy¹¹^*

¹Department of Haematology, Kings College Hospital, London, ENG, United Kingdom
²Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
³St Marys Hospital, Imperial College NHS FoundationTrust, London, United Kingdom
⁴St Marys Hospital, Imperial College NHS Foundation Trust London, London, GBR
⁵St Marys Hospital, Imperial College NHS Foundation Trust, London, United Kingdom
⁶St Marys Hospital, Imperial College NHS Foundation Trust, London, GBR
⁷Department of Paediatrics, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
⁸Division of Immunology and Inflammation, Imperial College London, London, United Kingdom
⁹Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom
¹⁰IMPERIAL COLLEGE HEALTHCARE NHS TRUST, London, United Kingdom
¹¹St Marys Hospital, Imperial College London, London, United Kingdom

3519

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Irwin Walker, MBBS^1,2, Uday Deotare, MBBS, MD, MScHQ^3,4,5^*, Mohamed Elemary, MD, MSc, PhD⁶^*, Mahmoud Elsawy, MD, MSc^7,8^*, Genevieve Gallagher, MD⁹^*, David Kliman, MBBS, FRACP, FRCPA¹⁰^*, Tony Panzarella, MSc¹¹^*, Nada Hamad, MBBS, MSc, BSc^12,13,14, Kirk R. Schultz, MD^15,16, Jan Storek, MD, PhD¹⁷ and Kristjan Paulson, MD¹⁸

¹Department of Medicine, McMaster University, Hamilton, ON, Canada
²Juravinski Cancer Centre, Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada
³Princess Margaret Cancer Centre, Toronto, ON, CAN
⁴Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada
⁵Department of Medicine, Division of Hematology, University of Western Ontario, London, ON, Canada
⁶Provincial Hematology and Blood and Marrow Transplant Program, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, SK, Canada
⁷Dalhousie University, Halifax, NS, Canada
⁸QEII Health Sciences Center, Halifax, NS, Canada
⁹Centre intégré de cancérologie, CHU de Québec - Université Laval, Québec, QC, Canada
¹⁰GenesisCare North Shore, St Leonards, NSW, Australia
¹¹University of Toronto, Toronto, ON, CAN
¹²St Vincent's Hospital, Sydney, NSW, Australia
¹³Haematology Department, The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia
¹⁴The University of New South Wales, Kensington, NSW, Australia
¹⁵University of British Columbia, Vancouver, BC, Canada
¹⁶B.C. Children's Hospital, Vancouver, BC, Canada
¹⁷The University of Calgary Department of Medicine, Calgary, Canada
¹⁸Cancercare Manitoba, Winnipeg, MB, Canada

3520

Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results

Antonio Bianchessi^1,2^*, Irene Defrancesco^1,3^*, Virginia Valeria Ferretti⁴^*, Cristina Picone⁵^*, Beatrice Ferrari⁵^*, Caterina Zerbi¹^*, Francesco Romano^1,2^*, Giulia Losi, MD^1,2^*, Erica Consensi⁵^*, Mara De Amici⁶^*, Giorgia Testa⁷^*, Valentina Zoboli¹^*, Alessia Taurino¹^*, Anna Amelia Colombo¹^*, Luca Arcaini^1,2^* and Nicola Polverelli¹

¹Unit of Bone Marrow Transplantation - Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
²Department of Molecular Medicine, University of Pavia, Pavia, Italy
³Deparment of Surgical, Clinical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
⁴Unit of Biostatistics and Clinical Trial Center, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
⁵Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
⁶Immuno-Allergology Laboratory of the Clinical Chemistry Unit and Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, ITA
⁷Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

3521

Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis

Joseph Rimando, MD¹, Michel Conn¹^*, William Blum, MD¹, Jason T Romancik, MD², Colin Vale, MD³^*, Amelia Langston, MD¹, Edmund K. Waller, MD, PhD¹ and Kevin Hall, PharmD¹^*

¹Emory University, Winship Cancer Institute, Atlanta, GA
²Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA
³Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

3522

Real-World Patient Characteristics and Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease Receiving Belumosudil in the United States

Jingbo Yu, MD, PhD¹^*, Kristin J. Moore, PhD, MPH²^*, Nicole M. Engel-Nitz, PhD, MS²^*, Mary DuCharme, MLIS²^*, Britnie Thomas, PhD¹^*, John Galvin, MD, MPH³ and Valkal Bhatt, PharmD¹^*

¹Incyte Corporation, Wilmington, DE
²Optum, Eden Prairie, MN
³Senior Medical Director, Incyte Corporation, Wilmington, DE

3523

Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease

Xinghao Yu^1,2^*, Yiyin Chen^1,2^*, Lei Lei^1,2^*, Dandan Lin^1,2^*, Ying Shen^1,2^*, Chang Hou^1,2^*, Jia Chen¹^*, Yi Fan¹^*, Huimin Lu³^*, Depei Wu, MD, PhD^2,4 and Yang Xu, MD^1,2^*

¹National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
²Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
³Department of outpatient and emergency, The First Affiliated Hospital of Soochow University, Suzhou, China
⁴The First Affiliated Hospital of Soochow University, Suzhou, China

3524

Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Sibgha Gull Chaudhary, MD^1,2,3^*, Moazzam Shahzad, MD^1,4, Kayla Pfannenstiell³^*, Muhammad Kashif Amin, MD^1,2,3^*, Amir Kasaeian^1,3^*, Muhammad Fareed Khalid, MD^1,3^*, Hediyeh Alemi^1,3^*, Naghmeh Khavandgar^1,3^*, Iqra Anwar, MBBS^1,3^*, Matthew McGuirk^1,3^*, Syed Nasir Abbas Bukhari^1,3^*, Anurag K. Singh, MD^1,2,3, Mehdi Hamadani, MD^1,5, Joseph P. McGuirk, DO^1,2,3 and Muhammad Umair Mushtaq^1,2,3

¹Mikael Rayaan Foundation Global Health Consortium, Kansas City, KS
²US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
³Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
⁴Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL
⁵Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

3525

T-allo10 Immunotherapy Results in Enhanced Early Immune Reconstitution and Reduced GvHD with Excellent Clinical Outcomes Post Αβ-Depleted HSCT in Pediatric and Young Adult Hematologic Malignancy Patients

Alice Bertaina, MD, PhD^1,2,3, Rosa Bacchetta, MD^1,2,3^*, Alma-Martina Cepika, MD, PhD^1,2^*, David C Shyr, MD^1,2,3, Giulia Barbarito, MS^1,2^*, Linda Oppizzi, BS^1,2^*, Pauline Chen, MD^1,2^*, Gopin Saini, MBBS^1,2^*, Jennifer Lee, PhD^1,2^*, Karen Kristovich, RN PNP^1,3^*, Rajni Agarwal, MD^2,4,5^*, Orly Klein, MD^1,2,3, Kathryn Melsop, MS^2,6^*, Keri Tate, PhD^2,6^*, Matthew Porteus, MD, PhD^1,2,3 and Maria Grazia Roncarolo, MD^1,2,3

¹Department of Pediatrics/ Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA
²Center for Definitive and Curative Medicine, Stanford University School of Medicine, Stanford, CA
³Lucile Packard Children’s Hospital, Palo Alto, CA
⁴Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA
⁵Lucile Packard Children’s Hospital, Palo Alto
⁶Laboratory for Cell and Gene Medicine, Stanford University School of Medicine, Palo Alto, CA

3526

Presence of Anti-D and Passive Transfer of Anti-D in Bone Marrow Transplant Patients Does Not Affect Transplant Outcomes

Rory McFarland, MD Candidate¹^*, Rida Hasan, MD¹ and Sandhya R. Panch, MD^2,3

¹University of Washington, Seattle, WA
²Fred Hutchinson Cancer Center, Seattle, WA
³Fred Hutchinson Cancer Center, Seattle

3527

Dynamics of Immune Reconstitution in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Matched Sibling Donor Stem Cell Transplantation: A Conventional and Computational Analysis

Elisabeth Dovern, MD¹^*, Tim R. Mocking^2,3^*, Mette D. Hazenberg, MD, PhD^4,5^*, Arjan A. van de Loosdrecht, MD, PhD^2,6^*, Simon Tol⁷^*, Erik Mul⁸^*, Boukje M. Beuger⁷^*, Robin Van Bruggen, PhD⁷^*, Myrddin Verheij, PhD^3,9^*, Carlijn Voermans, PhD^3,9^*, Costa Bachas, PhD^2,3^*, Bart J. Biemond¹ and Erfan Nur, MD, PhD^1,10

¹Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands
²Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands
³Department of Hematology, Amsterdam UMC location Vrije Universiteit, Amsterdam, Netherlands
⁴Department of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands
⁵Sanquin Research, Amsterdam, Netherlands
⁶Department of Hematology, Amsterdam University Medical Center, Free University, Amsterdam, Netherlands
⁷Department of Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands
⁸Department of Research Facilities, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands
⁹Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands
¹⁰Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands

3528

Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease

Scott R. Solomon, MD¹, Melissa Sanacore, PharmD¹^*, Lizamarie Bachier Rodriguez, MD¹, Latasha McCoy¹^*, Caitlin Guzowski, MBA¹^*, Katelin C Jackson¹^*, Xu Zhang, PhD²^*, H. Kent Holland, MD¹^*, Lawrence E Morris, MD¹, Melhem M. Solh, MD¹ and Asad Bashey, MD, PhD¹

¹Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA
²Center for Clinical and Transitional Sciences,, University of Texas, Houston, TX

3529

Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Victor Ling Wei Teik¹^*, Yeh Ching Linn²^*, Huirong Han¹^*, Michelle Poon, MBBS, MRCP¹^*, Lip Kun Tan¹^*, Joanne Shu Xian Lee¹^*, Yang Liang Boo, MD, MRCP¹^*, Ian Wu, MBBS, MRCP, MD¹^*, Jean Rachel Catapia, MD¹^*, Aloysius Yew Leng Ho², William Ying Khee Hwang², Yeow Tee Goh, MD², Francesca Lim, MBBS²^*, Hein Than, MD, FRCPath, MRCP², Lawrence Cheng Kiat Ng, MD²^*, Jeffrey Kim Siang Quek²^*, Tertius Tansloan Tuy, MD, MRCP(UK)²^*, Balamurugan Vellayappan³^*, Zi Yi Lim, MBBS, FRCP, FRCPath⁴^*, Colin Phipps Diong, MD⁵^*, Yvonne Loh⁶^*, Kheng Wei Yeoh⁷^*, Brian Ho⁷^*, Wen Shen Looi⁷^*, Yin Jie Koh¹^*, Teck Guan Soh¹^*, Kee Khiang Heng⁸^*, Gina Gan⁸^*, Wing Leung, PhD, MD⁹ and Liang Piu Koh¹^*

¹Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
²Department of Haematology, Singapore General Hospital, Singapore, Singapore
³Department of Radiation Oncology, National University Cancer Institute, Singapore, Singapore
⁴Centre for Clinical Haematology, Mount Elizabeth Novena Hospital, Singapore, Singapore
⁵Parkway Cancer Centre, Mount Elizabeth Hospital, Singapore, Singapore
⁶Curie Oncology, Singapore, Singapore
⁷Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore
⁸Singapore General Hospital, Singapore, Singapore
⁹KK Women’s and Children’s Hospital, Duke-NUS, Singapore, Singapore

3530

Effect of Age, Timing of Thrombotic Microangiopathy and Timing of Acute Graft-Versus-Host Disease on Overall Survival after Hematopoietic Stem Cell Transplantation

Udit Nangia, MD¹, Leland Metheny, MD² and Neeraj Mahajan, MD³^*

¹University Hospitals - Parma Medical Center, Vernon Hills, IL
²Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, OH
³University Hospitals - Parma Medical Center, Parma, OH

3531

Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)

Maria Carmen Martinez Munoz, MD, PhD¹^*, Leyre Bento De Miguel²^*, Maria Queralt Salas³^*, Juan Montoro⁴^*, Jaime Sanz⁵^*, Lucia Lopez Corral, MD⁶^*, Estefanía Pérez López, MD⁶^*, Maria Jesús Pascual, MD⁷^*, Irene García-Cadenas, MD⁸^*, Maria Suarez-Lledo, MD, PhD^9,10^*, Arancha Bermúdez¹¹^*, Felipe Peña, MD¹²^*, Carlos Carretero¹³^*, María-José Jiménez Lorenzo¹⁴^*, Pedro Antonio González¹⁵^*, Antonia Sampol Mayol¹⁶^*, Inmaculada Heras, MD¹⁷^*, Teresa Zudaire¹⁸^*, Pascual Balsalobre¹⁹^*, Silvia Filaferro¹⁹^*, Angel Cedillo²⁰^*, Carlos Solano, MD, PhD^21,22 and Manuel Jurado Chacón²³^*

¹Hematopoietic Cell Transplant Unit, Hospital Clinic of Barcelona, ICAMS, Barcelona, Spain
²Hematology Department, Son Espases University Hospital, IdISBa, Palma, Spain
³Hematopoietic Cell Transplantation Unit, Hospital Clínic de Barcelona, ICAMS, Barcelona, Spain
⁴Hematology Department, Hospital La Fe, Valencia, Spain
⁵Hematology Department, Hospital Universitari i Politècnic La Fe, Departament de Medicina Universitat de Valencia, CIBERONC, Instituto Carlos III, Spain, VALENCIA, Spain
⁶Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain
⁷Hematology Department, Hospital Regional Universitario de Málaga, Málaga, Spain
⁸Hematology Departmen, Hospital de Sant Pau, Barcelona, Spain
⁹Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Spain, Hospital Clínic de Barcelona, Barcelona, Spain
¹⁰Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain
¹¹Hospital Marques de Valdecilla (IDIVAL), Santander, Spain
¹²Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
¹³Hematology Department, Hospital Universitario Masqués de Valdecilla, Santander, Spain
¹⁴Hematology Department, Institut Català d’Oncologia de Badalona, Hospital Universitari Germans Trias i Pujol. Institut d’Investigació contra la Leucèmia Josep Carreras. Universitat Autònoma de Barcelona, Badalona, Spain
¹⁵Hematology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
¹⁶Hematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain
¹⁷Hematology Division, Hospital Morales Meseguer, Murcia, Spain
¹⁸Hematology Department, Complejo Hospitalario de Navarra, Pamplona, ESP
¹⁹Grupo Español de Trasplante de Progenitores Hematopoyéticos y Terapia Celular (GETH-TC) Data Office, Madrid, Spain
²⁰GETH Data Office, Madrid, Spain
²¹University of Valencia, Valencia, Spain
²²Hematology Department, Hematology Department, Hospital Clínico Universitario-INCLIVA, Valencia, Spain
²³Hospital Univ. Virgen de las Nieves, Granada, Spain

3532

Waning Long Term Efficacy of COVID-19 Post-Transplant Vaccination for Prevention of COVID-19 Adverse Events in Transplant and Cellular Therapy (TCT) Patients

Rahul Ramaswamy, MD¹^*, Laith Fakhoury, BS¹^*, Peter Zhao, MD¹^*, Ningying Wu, MD, PhD²^*, Feng Gao³^*, Geoffrey L. Uy, MD⁴, John F. DiPersio, MD, PhD⁵ and Zachary D. Crees, MD⁵

¹Washington University School of Medicine, St. Louis, MO
²Public Health Sciences Division, Washington University School of Medicine, St Louis, MO
³Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, Saint Louis, MO
⁴Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
⁵Division of Oncology, Washington University School of Medicine, Saint Louis, MO

3533

Regulatory Effects of IL-17A Monoclonal Antibody and Fibronectin on Chronic Graft-Versus-Host Disease

Yaqun Hong^1,2^*, Min Xu^1,2^*, Yuanzhong Chen²^*, Nainong Li, MD, PhD^1,3 and Xiaofan Li, MD, PhD^2,4

¹Fujian Medical University, Fuzhou, China
²Fujian Medical University Union Hospital, Fuzhou, China
³Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China
⁴Union Clinical Medical Colleges, Fujian Medical University, Fuzhou, China

3534

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Tamer Othman, MD¹, Dongyun Yang, PhD²^*, Sally Mokhtari, PhD³, Ibrahim Aldoss, MD⁴, Geoffrey Shouse, PhD, DO⁵, Shukaib Arslan, MD⁶^*, Leonardo Farol⁷^*, Leslie L. Popplewell, MD, MPH⁸, Ahmed Aribi, MD⁹^*, Alex F. Herrera, MD¹⁰, Lihua E. Budde, MD, PhD¹¹, Joshua Mansour, MD⁶^*, Matthew Mei, MD⁵, Karamjeet S Sandhu, MD¹², Tanya Siddiqi, MD, MBBS¹³^*, Jasmine Zain, MD¹⁰, Vaibhav Agrawal, M.D.¹², Idoroenyi Amanam, MD⁶, Vinod Pullarkat, MD¹⁴, Tycel J. Phillips, MD¹⁵, Ryotaro Nakamura, MD⁶, Stephen J. Forman, MD, FACP¹⁶ and Monzr M. Al Malki, MD¹⁰

¹Hematology/HCT, City of Hope, San Lorenzo, CA
²Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA
³Clinical and Translational Project Development, City of Hope National Medical Center, Duarte, CA
⁴Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Duarte Cancer Center, Duarte, CA
⁵City of Hope Cancer Center, Duarte, CA
⁶Hematology and HCT, City of Hope National Medical Center, Duarte, CA
⁷City of Hope, Daurte, CA
⁸City of Hope Cancer Treatment Center, Atlanta, GA
⁹Hematology/HCT, City of Hope National Medical Center, Duarte, CA
¹⁰City of Hope, Duarte, CA
¹¹Department of Hematology and HCT, City of Hope, Duarte, CA
¹²Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
¹³City of Hope National Medical Center, Duarte, CA
¹⁴City of Hope, La Canada, CA
¹⁵City of Hope, Pasadena, CA
¹⁶Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA

3535

Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial

Yin Liu^*, Ye Zhao^*, Xiaofei Qi^*, Qiao Cheng^*, Jia Chen^*, Xiao Ma^*, Shengli Xue^*, Ying Wang^*, Xiaowen Tang^*, Huiying Qiu^*, Yang Xu, MD^* and Depei Wu

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

3536

Spatial Characterization of Molecular Pathways Suggests the Dysregulation of LGR5 Expressing Fibroblasts in Patients with sclerodermatous Chronic Graft-Vs-Host Disease

Marjia Afrin, Ph.D.¹^*, Sahar Nasr¹^*, Cristabelle De Souza²^*, Brooke Howitt, MD, PhD³^*, Antonia Maria Mueller, MD⁴, Sally Arai, MD⁵, Judith Shizuru¹^* and Gerlinde Wernig, MD⁶^*

¹Stanford University, Stanford, CA
²Stanford, Stanford, CA
³Department of Pathology, Stanford University, Stanford, CA
⁴General Hospital Vienna, Vienna, Austria
⁵Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
⁶Stanford Hospital & Clinics, Stanford, CA

3537

Comparable OS and Gffs of ATLG Vs. Ratg for Gvhd Prophylaxis in Pediatric AA Patients Undergoing Transplantation

Li Nannan, MD¹^*, Yue Lu²^*, Deyan Liu²^*, Min Xiong³^*, Yanli Zhao^2,3^*, Ruijuan Sun^3,4^*, Zhijie Wei^2,3^*, Xingyu Cao^2,3^*, Jiarui Zhou^2,3^*, Jianping Zhang^2,3^* and Peihua Lu, MD^2,3,5

¹Hospital, Yanjiao Economic and Technological Devel, AL, CHN
²Hebei Yanda Lu Daopei Hospital, Langfang, China
³Beijing Lu Daopei Hospital, Beijing, China
⁴Hebei Yanda Lu Daopei Hospital, Beijing, China
⁵Beijing Lu Daopei Institute of Hematology, Beijing, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH